Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126188341 | 12618834 | 1 | I | 20160718 | 20160803 | 20160803 | PER | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-47155BP | BOEHRINGER INGELHEIM | 0.00 | F | Y | 68.04000 | KG | 20160803 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126188341 | 12618834 | 1 | PS | ATROVENT | IPRATROPIUM BROMIDE | 1 | Respiratory (inhalation) | 21527 | 17 | UG | INHALATION SOLUTION | ||||||||
| 126188341 | 12618834 | 2 | C | PREDNISONE. | PREDNISONE | 1 | Oral | 5 MG | 0 | 5 | MG | QD | |||||||
| 126188341 | 12618834 | 3 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG | 0 | 75 | MG | TABLET | QD | ||||||
| 126188341 | 12618834 | 4 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 10 MG | 0 | 10 | MG | TABLET | QD | ||||||
| 126188341 | 12618834 | 5 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MG | 0 | 20 | MG | CAPSULE | QD | ||||||
| 126188341 | 12618834 | 6 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Oral | 325 MG | 0 | 325 | MG | TABLET | QD | ||||||
| 126188341 | 12618834 | 7 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 20 MG | 0 | 20 | MG | TABLET | QD | ||||||
| 126188341 | 12618834 | 8 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | DOSE PER APPLICATION: 20 MG; FORMULATION: TABLET | 0 | QD | |||||||||
| 126188341 | 12618834 | 9 | C | MIRTAZAPINE. | MIRTAZAPINE | 1 | Oral | 15 MG | 0 | 15 | MG | TABLET | QD | ||||||
| 126188341 | 12618834 | 10 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 10 MG | 0 | 10 | MG | TABLET | QD | ||||||
| 126188341 | 12618834 | 11 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | 7142.8571 U | 0 | 50000 | IU | CAPSULE | /wk | ||||||
| 126188341 | 12618834 | 12 | C | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 60 MG | 0 | 20 | MG | TABLET | TID | ||||||
| 126188341 | 12618834 | 13 | C | FENTANYL. | FENTANYL | 1 | Topical | FORMULATION: PATCH | 0 | 25 | MG | ||||||||
| 126188341 | 12618834 | 14 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 0 | .5 | MG | TABLET | ||||||||
| 126188341 | 12618834 | 15 | C | BUDESOMIDE | 2 | Respiratory (inhalation) | FORMULATION: INHALATION SOLUTION; DOSE PER APPLICATION: 0.5 MG/2 ML; DAILY DOSE: 1MG /4 ML | 0 | BID | ||||||||||
| 126188341 | 12618834 | 16 | C | PERFOROMIST | FORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | FORMULATION: INHALATION SOLUTION; DOSE PER APPLICATION: 20 MCG/ 2 ML; DAILY DOSE: 40 MCG/ 4 ML | 0 | BID | |||||||||
| 126188341 | 12618834 | 17 | C | ALBUTEROL. | ALBUTEROL | 1 | Respiratory (inhalation) | FORMULATION: INHALATION SOLUTION; DOSE PER APPLICATION AND DAILY DOSE: 2.5 MG/ 3 ML; | 0 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126188341 | 12618834 | 1 | Dyspnoea |
| 126188341 | 12618834 | 2 | Product used for unknown indication |
| 126188341 | 12618834 | 3 | Product used for unknown indication |
| 126188341 | 12618834 | 4 | Product used for unknown indication |
| 126188341 | 12618834 | 5 | Product used for unknown indication |
| 126188341 | 12618834 | 6 | Product used for unknown indication |
| 126188341 | 12618834 | 7 | Product used for unknown indication |
| 126188341 | 12618834 | 9 | Product used for unknown indication |
| 126188341 | 12618834 | 10 | Product used for unknown indication |
| 126188341 | 12618834 | 11 | Product used for unknown indication |
| 126188341 | 12618834 | 12 | Product used for unknown indication |
| 126188341 | 12618834 | 13 | Product used for unknown indication |
| 126188341 | 12618834 | 14 | Product used for unknown indication |
| 126188341 | 12618834 | 15 | Product used for unknown indication |
| 126188341 | 12618834 | 16 | Product used for unknown indication |
| 126188341 | 12618834 | 17 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126188341 | 12618834 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126188341 | 12618834 | 1 | 201605 | 0 |